🚀 VC round data is live in beta, check it out!
Pacira BioSciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pacira BioSciences and similar public comparables like HK inno.N, Ventyx Biosciences, Philogen, Kaken Pharmaceutical and more.
Pacira BioSciences Overview
About Pacira BioSciences
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Founded
2006
HQ
Employees
790
Website
Financials (LTM)
EV
$1B
Pacira BioSciences Financials
Pacira BioSciences reported last 12-month revenue of $736M and EBITDA of $184M.
In the same LTM period, Pacira BioSciences generated $587M in gross profit, $184M in EBITDA, and $120M in net income.
Revenue (LTM)
Pacira BioSciences P&L
In the most recent fiscal year, Pacira BioSciences reported revenue of $726M and EBITDA of $186M.
Pacira BioSciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $736M | XXX | $726M | XXX | XXX | XXX |
| Gross Profit | $587M | XXX | $577M | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | $184M | XXX | $186M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $120M | XXX | $124M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | — | — | $214M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pacira BioSciences Stock Performance
Pacira BioSciences has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Pacira BioSciences' stock price is $24.72.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 3.6% | XXX | XXX | XXX | $3.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPacira BioSciences Valuation Multiples
Pacira BioSciences trades at 1.6x EV/Revenue multiple, and 6.4x EV/EBITDA.
EV / Revenue (LTM)
Pacira BioSciences Financial Valuation Multiples
As of April 19, 2026, Pacira BioSciences has market cap of $1B and EV of $1B.
Equity research analysts estimate Pacira BioSciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pacira BioSciences has a P/E ratio of 8.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 6.4x | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBIT | 7.7x | XXX | 7.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| P/E | 8.3x | XXX | 8.1x | XXX | XXX | XXX |
| EV/FCF | 8.4x | XXX | 8.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pacira BioSciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Pacira BioSciences Margins & Growth Rates
Pacira BioSciences' revenue in the last 12 month grew by 6%.
Pacira BioSciences' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.7M for the same period.
Pacira BioSciences' rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pacira BioSciences' rule of X is 35% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Pacira BioSciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | (5%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 20% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 16% | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 75% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Pacira BioSciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pacira BioSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| HK inno.N | XXX | XXX | XXX | XXX | XXX | XXX |
| Ventyx Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Philogen | XXX | XXX | XXX | XXX | XXX | XXX |
| Kaken Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Strides Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pacira BioSciences M&A Activity
Pacira BioSciences acquired XXX companies to date.
Last acquisition by Pacira BioSciences was on XXXXXXXX, XXXXX. Pacira BioSciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Pacira BioSciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPacira BioSciences Investment Activity
Pacira BioSciences invested in XXX companies to date.
Pacira BioSciences made its latest investment on XXXXXXXX, XXXXX. Pacira BioSciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Pacira BioSciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pacira BioSciences
| When was Pacira BioSciences founded? | Pacira BioSciences was founded in 2006. |
| Where is Pacira BioSciences headquartered? | Pacira BioSciences is headquartered in United States. |
| How many employees does Pacira BioSciences have? | As of today, Pacira BioSciences has over 790 employees. |
| Who is the CEO of Pacira BioSciences? | Pacira BioSciences' CEO is Frank D. Lee. |
| Is Pacira BioSciences publicly listed? | Yes, Pacira BioSciences is a public company listed on Nasdaq. |
| What is the stock symbol of Pacira BioSciences? | Pacira BioSciences trades under PCRX ticker. |
| When did Pacira BioSciences go public? | Pacira BioSciences went public in 2011. |
| Who are competitors of Pacira BioSciences? | Pacira BioSciences main competitors are HK inno.N, Ventyx Biosciences, Philogen, Kaken Pharmaceutical. |
| What is the current market cap of Pacira BioSciences? | Pacira BioSciences' current market cap is $1B. |
| What is the current revenue of Pacira BioSciences? | Pacira BioSciences' last 12 months revenue is $736M. |
| What is the current revenue growth of Pacira BioSciences? | Pacira BioSciences revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Pacira BioSciences? | Current revenue multiple of Pacira BioSciences is 1.6x. |
| Is Pacira BioSciences profitable? | Yes, Pacira BioSciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pacira BioSciences? | Pacira BioSciences' last 12 months EBITDA is $184M. |
| What is Pacira BioSciences' EBITDA margin? | Pacira BioSciences' last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Pacira BioSciences? | Current EBITDA multiple of Pacira BioSciences is 6.4x. |
| What is the current FCF of Pacira BioSciences? | Pacira BioSciences' last 12 months FCF is $141M. |
| What is Pacira BioSciences' FCF margin? | Pacira BioSciences' last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Pacira BioSciences? | Current FCF multiple of Pacira BioSciences is 8.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.